Home Blog
The vast potential of next-gen therapies
The complexities of next-generation therapies are pushing the boundaries of development and manufacture, leading to an increased need for advanced technologies and novel approaches...
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Eli Lilly and Company and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other...
$149 a month new oral GLP-1 pill for weight loss (Foundayo...
Eli Lilly and Company has announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the US Food...
European Commission approves Kygevvi (doxecitine and doxribtimine) as first and only treatment...
UCB, a global biopharmaceutical company, has announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine)...
Romaco Group appoints Nicola Magriotis as Chief Sales Officer
The advisory board of Romaco Holding GmbH has appointed Nicola Magriotis as Chief Sales Officer (CSO) of the Romaco Group. By creating this new managerial...
New report finds FDA costs soaring and drug rejections rising
The Taxpayers Protection Alliance released a report, called Blocking Breakthroughs: Delays and Denials at the FDA, that highlights the many issues with the Food and Drug...
Eisai and Nuvation Bio announce marketing authorisation application for taletrectinib for...
Eisai Co, a human-centred global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio, a global oncology company...
Ellison purchase swells triangle’s lab space
Oxfordshire, a key part of UK life sciences’ Golden Triangle region, had an annual take-up of lab space last year amounting to 620,200 sq...
Inaugural International Brain Health Conference 2026 to focus on early intervention before...
International Brain Health Conference 2026 18–19 May 2026 Sheraton Grand Hotel, Edinburgh, UK
An international conference bringing together global leaders in neuroscience, clinical research, public health, and...
Seda accelerates global pharma growth with £15m backing from BGF
BGF, the UK and Ireland’s most active growth capital investor, has completed a £15 million investment in Seda Pharma Development Services Ltd (Seda), an integrated...
Enzymatica and STADA sign partnership agreement for Germany and Austria
Enzymatica AB and STADA Arzneimittel AG have entered into a partnership agreement regarding the launch and distribution of Enzymatica’s ColdZyme® oral-spray technology in Germany...